Craneware plc (CRWRF) Stock

About Craneware plc

Craneware plc, alongside its various subsidiaries, is dedicated to developing, licensing, and providing ongoing support for specialized software solutions within the United States healthcare industry. The company's comprehensive suite of products addresses a wide range of operational and financial needs. For revenue cycle and financial management, Craneware offers Trisus pricing transparency software, designed to clarify pricing information, along with Trisus Pricing Analyzer to automate and simplify price modeling. Its Trisus Chargemaster provides automated management of chargemaster data, while InSight Audit assists government and commercial payors with audit processes. Additionally, InSight Denials facilitates the analysis, tracking, and reporting of claims denial data, and Trisus Claims Informatics offers retrospective analytical insights to identify charge capture risks. In the realm of clinical operations and supply chain, solutions include InSight Medical Necessity, which helps U.S. payors determine medical necessity; Trisus Supply, aimed at enhancing reimbursement for medical supplies; and Trisus Healthcare Intelligence, delivering patient-level insights into resource consumption. The portfolio also extends to Trisus Medication Analytic and Trisus Supplies Assistant solutions. Craneware also features a specialized line of pharmacy and drug tracking software. This includes Sentinel for drug tracking, Sentrex (a SaaS platform enabling covered entities to expand medication access), Sentrex 330, a Referral Verification System, and Sentry Core, which streamlines the complexities of pharmacy procurement, utilization, and compliance. Beyond its software offerings, Craneware provides professional and appeal services. The company was founded in 1999 and is headquartered in Edinburgh, United Kingdom.

Craneware plc is headquartered in GB.

Craneware plc (CRWRF) stock trades at $15.23 with a market capitalization of $521.43M. The stock is valued at a price-to-earnings (P/E) ratio of 25.52, price-to-book of 1.66, price-to-sales of 2.60. Over the past 52 weeks the stock has ranged between $15.23 and $34.00, and currently trades 55.2% below its 52-week high. It pays a dividend yielding 2.63%.

On profitability, Craneware plc generates a return on equity (ROE) of 6.65%, return on capital employed of 7.32%, an operating margin of 13.56%, a net profit margin of 10.63%.

Official website: www.thecranewaregroup.com